Prediction of the Risk of Placental Vascular Pathology and Venous Thromboembolic Disease

Study Overview
=================
Brief Summary
-----------------
Venous thromboembolic (VTE) disease is the first cause of maternal mortality in the world. Some other pregnancy pathologies called Placental Vascular Pathologies (PVP) are linked to VTE by biological thrombophilia and are the principal cause of perinatal mortality. the identification of predictive factors of risk of occurrence or recurrence of two pathologies could enable us to propose an appropriate monitoring of patients at risk.

Detailed Description
-----------------
Main aim: To evaluate echographic, doppler and biological markers in a prospective manner as a potential predictive factor of risk of PVP and VTE.

Official Title
-----------------
Prediction of the Risk of Placental Vascular Pathology and Venous Thromboembolic Disease: Role of Angiogenic Factors, Hemostasis and Uterine Artery Doppler

Conditions
-----------------
Placental Vascular Pathologies, Venous Thromboembolism Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: previous history of one or more PVC episodes (preeclampsia, HELLPs, retroplacental hematoma, vascular IUGR<10th percentile, recurrence miscarriage >2, unexplained IUFD or IUFD after abruption placentae, eclampsia. Previous history of personal VTE Diabete (treated with diet or insulin) chronic hypertension chronic renal pathology lupus obesity Antihopholipids syndrome early and late pregnancy (<18 years, >38 years) family history of cardiovascular disease of VTE known biological thrombophilia without any personal past history of PVC or VTE Exclusion Criteria: Multiple pregnancy past history of in utero fetal death due to congenital malformations, rhesus incompatibility or an infection previous history of IUGR which etiology was a chromosomal, genic or infectious anomaly

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>pregnancy women | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| sFlt1/plGF ratio |  | 20, 24, 28, 32, 36 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SFlt1/PlGF ratio as predictive threshold to develop a PVP and/or a VTE |  | 20, 24, 28, 32, 36 SA | 
| thrombin generation test (TGT) as potential predictive factor risck oj PVP and VTE |  | 20, 24, 28, 32 and 36 weeks | 
| sEng, rTFPI, D-Dimer, uCRP, PP13 as potential predictive factor of risk of PVP and or VTE |  | 20, 24, 28, 32 and 36 weeks | 
| echographic data as potential predictive factors of VTE and or PVP |  | 22 and 32 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
preeclampsia, eclampsia, retroplacental hematoma, vascular IUGR, IUFD, VTE